Multicenter study of in vitro activity of tigecycline in clinical isolates from 30 centers in Spain;Estudio multicéntrico de la actividad in vitro de tigeciclina en aislados clínicos en 30 hospitales españoles

Revista Espanola de Quimioterapia

Volumn 22, Issue 2, 2009, Pages 76-82

  Garcia Rodriguez J A ^a   Otero, I ^b   Coira, M A ^c   Martinez Martinez, L ^d   Fernandez M I ^e   Tinajas, A ^f   Paz, I ^f   Michaus, L ^g   Sierra, G ^h   Ojeda, E ⁱ   Prats, G ^j   Matas, L ^k   De Batlle, J ^l   Mirelis, B ^m   Llucian, R ⁿ   Royo, G ^o   Pastor, E ^o   Perez J L ^p   Alberola, J ^q   Crespo, M D ^r   Bisquert, J ^s   Buezas, V ^t   Del Alamo M ^u   Fresnadillo, M J ^a   Fernandez R ^v   Romero, D ^w   Ferrero, M ^x   Casal, M ^y   Rodriguez, F ^y   Sanchez Yebra W ^z   Calbo, L ^aa   Teno, P ^ab   Porras, J A ^ac   Lafarga, B ^ad   more..

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b HOSPITAL XERAL CÍES   (Spain)

^c HOSPITAL XERAL CALDE   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^e HOSPITAL DE LEÓN   (Spain)

^f Hospital Cristal Pinor   (Spain)

^g HOSPITAL TXAGORRITXU   (Spain)

^h HOSPITAL SAN AGUSTÍN   (Spain)

ⁱ HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^j HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^k HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^l HOSPITAL JOSEP TRUETA   (Spain)

^m HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

ⁿ HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^o HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^p HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^q HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^r HOSPITAL PERPETUO SOCORRO   (Spain)

^s Hospital de Guadalajara   (Spain)

^t HOSPITAL CENTRAL DE LA DEFENSA GÓMEZ ULLA   (Spain)

^u HOSPITAL SEVERO OCHOA   (Spain)

^v Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^w Hospital Alarcos   (Spain)

^x HOSPITAL SAN JORGE   (Spain)

^y Hospital Universitario Reina Sofia Cordoba   (Argentina)

^z HOSPITAL TORRECÁRDENAS   (Spain)

^aa HOSPITAL DE JEREZ   (Spain)

^ab Hospital San Pedro de Alcantara   (Brazil)

^ac HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^ad HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

more..

Author keywords

Multicenter study; Tigecycline

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFEPIME; CEFOTAXIME; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN; ANTIINFECTIVE AGENT; DRUG DERIVATIVE; MINOCYCLINE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; DRUG POTENCY; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; KLEBSIELLA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATHOGENESIS; SPAIN; CLINICAL TRIAL; DRUG EFFECT; DRUG SCREENING; ENTEROCOCCUS FAECALIS; ENZYMOLOGY; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; HOSPITAL LABORATORY; HUMAN; IN VITRO STUDY; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTICENTER STUDY; MULTIDRUG RESISTANCE; RETROSPECTIVE STUDY;

ANTI-BACTERIAL AGENTS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; KLEBSIELLA; LABORATORIES, HOSPITAL; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; RETROSPECTIVE STUDIES; SPAIN;

EID: 70349573314     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Cuevas O, Cercenado E, Vindel A, Guinea J, Sanchez-Conde M, Sanchez-Somolinos M, et al. Evolution of the antimicrobial resistance of Staphylococcus spp. in Spain: five nationwide prevalence studies, 1986 to 2002. Antimicrob Agents Chemother 2004;48:4240-4245
2. Hernandez JR, Pascual A, Canton R, Martinez-Martinez L. [Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Spanish hospitals (GEIH-BLEE Project 2002)]. Enferm Infecc Microbiol Clin 2003;21:77-82.
3. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE, Jr. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 2004;38:1279-1286
4. Gobernado M. Bacterial resistance and a new antibiotic: tigecycline. Rev Esp Quimioter 2006;19:209-219
5. Kazakova SV, Hageman JC, Matava M, Srinivasan A, Phelan L, Garfinkel B, et al. A clone of methicillin-resistant Staphylococcus aureus among professional football players. N Engl J Med 2005;352:468-475 (Pubitemid 40175973)
6. Naimi TS, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. Jama 2003;290:2976-2984
7. Vandenesch F, Naimi T, Enright MC, Lina G, Nimmo GR, Heffernan H, et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 2003;9:978-984
8. Morin CA, Hadler JL. Population-based incidence and characteristics of community-onset Staphylococcus aureus infections with bacteremia in 4 metropolitan Connecticut areas, 1998. J Infect Dis 2001;184:1029-1034
9. Crowcroft NS, Catchpole M. Mortality from methicillin resistant Staphylococcus aureus in England and Wales: analysis of death certificates. Br Med J 2002;325:1390-1391 (Pubitemid 35477843)
10. Jones RN. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). Semin Respir Crit Care Med 2003;24:121-134.
11. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003;31:481-498
12. Rodriguez-Bano J, Navarro MD, Romero L Martinez-Martinez L, Muniain MA, Perea EJ, et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004;42:1089-1094 (Pubitemid 38332830)
13. Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005;56:52-59 (Pubitemid 41418336)
14. Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005;41(Suppl 5): S303-314.
15. CLSI. CaLSIPsfastFisDM-SWP.
16. Sum PE, Petersen P. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg Med Chem Lett 1999;9:1459-1462
17. Testa RT, Petersen PJ, Jacobus NV, Sum PE, Lee VJ, Tally FP. in vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines. Antimicrob Agents Chemother 1993;37: 2270-2277
18. Frampton JE, Curran MP. Tigecycline. Drugs 2005;65:2623-2635
19. Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ. in vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 2005;52:215-227
20. Bradford PA, Weaver-Sands DT, Petersen PJ. in vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005;41(Suppl 5):315-332
21. Betriu C, Rodriguez-Avial I, Gomez M, Culebras E, Lopez F, Alvarez J, et al. Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study. Diagn Microbiol Infect Dis 2006;56: 437-444
22. Morosini MI, Garcia-Castillo M, Coque TM, Valverde A, Novais A, Loza E, et al. Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Chemother 2006;50:2695-2699 (Pubitemid 44198689)
23. Sorlozano A, Gutierrez J, Salmeron A, Luna JD, Martinez-Checa F, Roman J, et al. Activity of tigecycline against clinical isolates of Staphylococcus aureus and extended-spectrum beta-lactamase-producing Escherichia coli in Granada, Spain. Int J Antimicrob Agents 2006;28: 532-536 (Pubitemid 44779174)
24. Bouchillon SK, Hoban DJ, Johnson BM, Johnson JL, Hsiung A, Dowzicky MJ. in vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004). Diagn Microbiol Infect Dis 2005;52:173-179
25. Gales AC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis 2000;36:19-36.
26. Milatovic D, Schmitz FJ, Verhoef J, Fluit AC. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 2003;47:400-404 (Pubitemid 36070396)
27. Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004). Diagn Microbiol Infect Dis 2005;52:195-201.
28. Long SSea: Principles and practice of pediatric infectious diseases. New York: Churchill Livingstone, 1997; pp. 780-793
29. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-136 (Pubitemid 27341646)
30. Staphylococcus aureus with reduced susceptibility to vancomycin - Illinois, 1999. MMWR Morb Mortal Wkly Rep 2000;48:1165-1167
31. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep 2002;51:565-567
32. Karabinis A, Paramythiotou E, Mylona-Petropoulou D, Kalogeromitros A, Katsarelis N, Kontopidou F, et al. Colistin for Klebsiella pneumoniae-associated sepsis. Clin Infect Dis 2004;38:7-9.
33. Kasbekar N. Tigecycline: A new glycylcycline antimicrobial agent. Am J Health Syst Pharm 2006;63:1235-1243 (Pubitemid 44025089)
34. Lázaro E and Otero J. Evolución del consumo y de la resistencia a antibióticos en España. Inf Ter Sist Nac Salud 2006;30:10-19